PEMBROLIZUMAB

Pembrolizumab is a humanized monoclonal antibody that blocks PD1 on T cells, restoring antitumor immune responses. It is used in various cancers including melanoma, lung cancer, and Hodgkin lymphoma. Benefits include durable responses and improved survival in responsive patients. Side effects include immunerelated adverse events such as colitis, hepatitis, pneumonitis, endocrinopathies, skin reactions, and fatigue. Only GMP materials will be supplied, logistics all according to GDP.

SKU: 05677ed34c4a Category: Tag:

Product Description


Mechanism of Action

PEMBROLIZUMAB exhibits a multidimensional biochemical activity profile involving modulation of enzyme-catalyzed pathways, receptor-mediated intracellular signaling, ion-channel regulation, mitochondrial bioenergetics, oxidative-stress balancing, membrane dynamics, and transcription-factor orchestration. Its molecular configuration allows high-affinity interaction with catalytic residues, allosteric domains, regulatory scaffolds, and signaling intermediates, influencing phosphorylation cycles, secondmessenger flux (Ca²⁺, cAMP, IP, DAG), ROS equilibrium, ATP synthesis, and mitochondrial respiratory-chain regulation.

Depending on dose, exposure duration, and cell type, PEMBROLIZUMAB can modify chromatin accessibility, metabolic flux routing, vesicular trafficking, cytoskeletal structure, and gene-expression clusters associated with survival, inflammation, apoptosis, autophagy, and metabolic adaptation.

Benefits and Advantages

Due to its consistent mechanistic behavior, this compound is utilized in advanced research, including:

  • Receptorligand interaction studies and affinity modeling
  • Highresolution enzyme kinetics and catalytic-pathway deconstruction
  • Mitochondrial ATPflux assays and oxidativestress system modeling
  • Multiomics profiling (transcriptomics, proteomics, metabolomics, phosphoproteomics)
  • Cytoskeletal and membranedynamics exploration
  • Apoptosis, ferroptosis, necroptosis, and autophagy pathway analysis
  • Structureactivity relationship (SAR) investigations and compound optimization
  • Pharmacodynamic modeling, mechanistic doseresponse scaling, and pathway benchmarking

Side Effects and Risks

Potential laboratory risks include:

  • Oxidativestress imbalance and ROS accumulation
  • Mitochondrial overload or respiratory-chain suppression
  • Ionchannel dysregulation affecting Ca²⁺/Na⁺/K⁺ homeostasis
  • Unintended receptor crossactivation or pathway inhibition
  • Cytoskeletal destabilization and membrane-integrity disruption
  • Dose-dependent cytotoxicity (apoptotic or autophagic induction)
  • Transcriptional or epigenetic instability under prolonged exposure
  • Activation of inflammatory signaling networks (NF-κB, JNK, p38 MAPK)

Use strictly in controlled laboratory environments with appropriate biosafety protocols.

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Formula

Protein

Molecular Weight

149000.0 g/mol

CAS Number

1374853-91-4

Storage Condition

Store at 2-8°C

Solubility

Soluble in water

Purity

Purity information is available upon request (COA).

Synonym

Lambrolizumab

IUPAC/Chemical Name

Humanized anti€‘PD€‘1 monoclonal antibody

InChl Key

Unavailable

InChl Code

Unavailable

References

PubChem; ChemBL; FDA;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download